Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan ir@chordiatherapeutics.com



This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Pre><Press Release>
15th October 2025

Company: Chordia Therapeutics Inc.
Representative: Chief Executive Officer Hiroshi Miyake

(Security Code: 190A TSE Growth Market)
Contact: IR Manager Ami Kira

<u>Publication of Research on the Discovery of CLK Inhibitor Rogocekib</u> <u>(Follow-up announcement)</u>

Kanagawa Japan

15th October 2025 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, "Chordia") announces that the research paper of the discovery of our CLK inhibitor rogocekib (CTX-712), which was recently published online in *ACS Medicinal Chemistry Letters* on September 20, 2025, has been selected for the ACS Editors' Choice[®] and featured as the Supplementary Cover Art of the journal.

Selection for ACS Editors' Choice®

ACS Editors' Choice[®] is a prestigious recognition program in which world-renowned scientific editors select one exceptional paper each day from among more than 64 peer-reviewed journals published by the American Chemical Society (ACS). The selected articles are made freely accessible for a limited period and are prominently highlighted to ACS members and journal subscribers.

URL: https://pubs.acs.org/editorschoice

We believe that the selection of our paper in ACS Medicinal Chemistry Letters for ACS Editors' Choice® highlights the strength of our drug discovery research capabilities and serves as compelling evidence that rogocekib is garnering significant attention from the ACS and the broader scientific community.

Selection for Supplementary Cover Art

The scientific value of research results on the discovery of rogocekib published in ACS Medicinal Chemistry Letters has been highly recognized and selected for the Supplementary Cover Art of Volume 16, Issue 10 of the journal.

URL: https://pubs.acs.org/toc/amclet/16/10

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan ir@chordiatherapeutics.com



Publication Details

The paper was selected as an ACS Editors' Choice®, and is currently available free of charge for a limited time through the ACS Publications website.


Discovery of Rogocekib (CTX-712): A Potent and Selective CLK Inhibitor for Cancer Treatment

ACS Medicinal Chemistry Letters, 2025, 16 (10), 1870-1875.

URL: https://doi.org/10.1021/acsmedchemlett.5c00412

About the Illustration of Supplementary Cover Art

Splicing is the process of removing non-coding regions from mRNA that are not translated into proteins. The graphic illustration selected for the Supplementary Cover Art visually represents how the CLK inhibitor rogocekib alters splicing, thereby inducing stress in cancer cells and ultimately leading to cell death—all captured in a single illustration.



Reproduced with permission from *ACS Medicinal Chemistry Letters*, **2025**, *16* (10), 1870-1875. © 2025 American Chemical Society.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan ir@chordiatherapeutics.com



About the Journal

ACS Medicinal Chemistry Letters is an international journal published by the American Chemical Society (ACS), dedicated to the rapid dissemination of innovative research in medicinal chemistry and drug discovery. The journal covers a wide range of topics including small-molecule design, target identification, mechanism of action studies, structure optimization, and pharmacokinetics.

About Chordia Therapeutics

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please contact our website https://www.chordiatherapeutics.com/en/.